Ipsen says to seek approval for muscle-spasm drug
PARIS (Reuters) - French drugmaker Ipsen said that it would begin the process of regulatory approval for a muscle-spasm drug, branded Dysport Next Generation, after a liquid-toxin trial showed it was "safe and efficacious".
"On the basis of these results and feedback from the principal investigator of the Phase III study, Ipsen intends to initiate a dialogue with key agencies on the regulatory approach to file the first ready-to-use liquid toxin A in Europe and rest-of-world," Ipsen said.
(Reporting by Lionel Laurent)
- Malaysia military tracked missing plane to west coast: source |
- Malaysia air probe finds scant evidence of attack: sources |
- Ukraine forms new defense force, seeks Western help |
- UPDATE 1-Missing Malaysian plane last seen at Strait of Malacca-source
- Freescale loss in Malaysia tragedy leads to travel policy questions